SecSonar.com

CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

CRISPR Therapeutics AG (CRSP) is a Biotechnology company based in CH with a market capitalization of $5.4B. Revenue declined 90.0% year-over-year and free cash flow was negative at -$345.9M. This page tracks CRSP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

CH · 393 employees · IPO Oct 19, 2016

Valuation

Valuation & price

$51.70 · as of May 26, 2026 · -32.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.81

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$76.78$61.27$45.75Jul 25Dec 25Jul 26Jul 7, 25$51.19Jul 9, 25$60.08Jul 11, 25$56.80Jul 15, 25$52.73Jul 17, 25$55.09Jul 21, 25$65.33Jul 23, 25$68.14Jul 25, 25$64.76Jul 29, 25$59.02Jul 31, 25$56.26Aug 4, 25$59.59Aug 6, 25$56.34Aug 11, 25$55.41Aug 13, 25$57.33Aug 15, 25$59.73Aug 19, 25$54.16Aug 21, 25$52.82Aug 25, 25$54.13Aug 27, 25$53.53Aug 29, 25$51.83Sep 3, 25$52.98Sep 5, 25$54.86Sep 9, 25$53.69Sep 11, 25$55.89Sep 16, 25$61.19Sep 18, 25$62.94Sep 22, 25$62.10Sep 24, 25$61.05Sep 26, 25$61.67Sep 30, 25$64.81Oct 2, 25$72.82Oct 6, 25$70.19Oct 8, 25$76.78Oct 10, 25$73.07Oct 14, 25$69.38Oct 16, 25$68.43Oct 21, 25$72.32Oct 23, 25$67.21Oct 27, 25$65.72Oct 29, 25$62.56Oct 31, 25$63.99Nov 4, 25$56.41Nov 6, 25$56.61Nov 10, 25$54.58Nov 12, 25$52.19Nov 14, 25$52.53Nov 18, 25$53.47Nov 20, 25$49.29Nov 25, 25$53.57Nov 28, 25$53.47Dec 2, 25$51.58Dec 4, 25$58.18Dec 8, 25$57.36Dec 10, 25$57.59Dec 12, 25$56.68Dec 16, 25$55.97Dec 18, 25$54.84Dec 22, 25$57.91Dec 24, 25$56.71Dec 29, 25$53.97Jan 2, 26$53.77Jan 6, 26$58.19Jan 8, 26$56.40Jan 12, 26$55.30Jan 14, 26$56.89Jan 16, 26$53.51Jan 21, 26$54.73Jan 23, 26$55.52Jan 27, 26$54.26Jan 29, 26$53.35Feb 2, 26$51.31Feb 4, 26$50.17Feb 9, 26$49.70Feb 11, 26$48.32Feb 13, 26$53.07Feb 18, 26$53.52Feb 20, 26$53.46Feb 24, 26$56.77Feb 26, 26$61.74Mar 2, 26$60.77Mar 4, 26$60.00Mar 6, 26$56.50Mar 10, 26$52.80Mar 12, 26$48.87Mar 17, 26$50.09Mar 19, 26$46.95Mar 23, 26$46.88Mar 25, 26$47.09Mar 27, 26$45.75Mar 31, 26$47.57Apr 2, 26$49.51Apr 7, 26$49.70Apr 9, 26$51.72Apr 13, 26$54.83Apr 15, 26$56.76Apr 17, 26$57.99Apr 22, 26$56.42Apr 24, 26$48.79Apr 28, 26$52.06Apr 30, 26$52.34May 4, 26$53.58May 6, 26$55.08May 8, 26$54.83May 12, 26$52.83May 14, 26$50.45May 18, 26$48.56May 20, 26$48.55May 22, 26$50.36May 28, 26$56.38Jun 1, 26$54.19Jun 3, 26$52.08Jun 5, 26$51.84Jun 9, 26$51.48Jun 11, 26$50.23Jun 15, 26$52.61Jun 17, 26$53.09Jun 22, 26$54.36Jun 24, 26$53.55Jun 26, 26$54.92Jul 2, 26$60.08
$44.3452-week range$76.78
Loading valuation history…

Fundamentals

Key fundamentals

$5.4B

Market cap

-90.0%

Revenue growth (YoY)

-6537.0%

Gross margin

-$345.9M

Free cash flow (USD)

-$1.6B

Net debt

Net cash position

6.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$5.2MFY 2017$41.0MFY 2018$3.1MFY 2019$289.6MFY 2020$719.0KFY 2021$913.1MFY 2022$436.0KFY 2023$370.0MFY 2024$35.0MFY 2025$3.5M
$5.2M$3.5M

Free cash flow by year

2016 → 2025

FY 2016$-58.3MFY 2017$-77.9MFY 2018$-99.0MFY 2019$50.0MFY 2020$-256.7MFY 2021$457.3MFY 2022$-532.9MFY 2023$-269.8MFY 2024$-144.7MFY 2025$-345.9M
-$58.3M-$345.9M

Gross margin by year

2021 → 2025

FY 202188.9%FY 2022-25186.7%FY 202364.8%FY 2024-215.0%FY 2025-6537.0%
88.9%-6537.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 4, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventArticles of AssociationJun 4, 2026Filing
  • 8-K eventEarnings ReleaseMay 4, 2026Filing
  • Quarterly report10-Q FiledMay 4, 2026Filing

Questions

Frequently asked questions

What is CRISPR Therapeutics AG's market cap?

CRISPR Therapeutics AG (CRSP) has a market capitalization of $5.4B.

What is CRSP's P/E ratio?

A meaningful P/E ratio is not available for CRSP — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CRSP's price-to-book (P/B) ratio?

CRSP trades at 2.81 times book value per share.

Are insiders buying CRSP stock?

SEC Form 4 filings show no open-market insider buys at CRISPR Therapeutics AG in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

CGON

CG Oncology, Inc. Common stock

$5.4B

LQDA

Liquidia Corporation

$5.5B

MIRM

Mirum Pharmaceuticals, Inc.

$5.1B

LEGN

Legend Biotech Corporation

$5B

TGTX

TG Therapeutics, Inc.

$5.9B

CAI

Caris Life Sciences, Inc.

$4.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.